期刊文献+

肥胖儿童伴黑棘皮病糖代谢特征及二甲双胍干预治疗58例 被引量:2

Characteristics of glycometabolism in 58 corpulent children with acanthosis nigricans and interfering treatment with metformin
下载PDF
导出
摘要 目的 :观察中、重度肥胖伴黑棘皮病病儿的糖代谢特征 ,二甲双胍干预治疗对糖、脂代谢的影响。方法 :选择中、重度肥胖病儿 5 8例 ,分为伴有黑棘皮病 (32例 )和不伴黑棘皮病 (2 6例 ) 2组 ,均予二甲双胍 5 0 0mg ,po ,bid× 8wk。结果 :(1)伴有黑棘皮病组治疗前空腹胰岛素 (FINS)为 (43±s 13)mU·L- 1、餐后 2h胰岛素 (PINS)为 (12 8± 2 3)mU·L- 1明显高于不伴黑棘皮病组 (30± 11)mU·L- 1,(5 8± 9)mU·L- 1(P <0 .0 1) ;(2 )二甲双胍干预治疗 8wk ,2组FINS ,PINS ,总胆固醇 (TC) ,三酰甘油 (TG) ,均有非常明显下降 (P <0 .0 1) ,胰岛素敏感指数 (IAI)上升 (P <0 .0 1) ,2组不良反应轻微。结论 :肥胖伴黑棘皮病病儿多存在高胰岛素血症、胰岛素抵抗 ,二甲双胍干预治疗能减轻胰岛素抵抗 ,增加机体对胰岛素的敏感性。 AIM: To observe the characteristics of glycometabolism in moderate to severe corpulent children with acanthosis nigricans and the effects of metformin in interfering treatment of glycometabolism and lipometabolism. METHODS: Fifty-eight patients with moderate to severe adiposis were divided into two groups. Acanhthosis nigricans (AN) group (32 patients) and without AN group (26 patients). All patients were treated with metformin 500 mg, po, bid for 8 wk. RESULTS: (1) Fasting insulin(FINS) in AN group was (43±s 13) mU·L -1 and 2 post-meal insulin (PINS) was (128±23) mU·L -1 before the treatment, those were significantly higher than those in without AN group (FINS(30±11) mU·L -1 and PINS(58±9)mU·L -1)(P<0.01); (2)Two groups FINS, PINS, TC, and TG significantly decreased (P<0.01) and the insulin-sensitivily index (IAI) increased (P<0.01) after 8 wk interfering treatment with metformin. The adverse reactions of two groups were mild. CONCLUSION: There are hyperinsulinism and insulin-resistant in corpulent children with AN. The interfering treatment with metformin can decrease insulin-resisatant and increase insulin-sensitivity to body.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2004年第6期363-365,共3页 Chinese Journal of New Drugs and Clinical Remedies
关键词 肥胖症 胰岛素 二甲双胍 黑棘皮病 obesity insulin metformin acanthosis nigricans
  • 相关文献

参考文献6

  • 1STUART CA, DRISCOLL MS, LUNDQUIST KF, et al. Acanthosis nigricans[J]. J Basic Clin Physiol Pharmacol, 1998, 9(2-4):407-418.
  • 2EHTISHAM S, BARRETT TG, SHAW NJ. Type 2 diabetes mellitus in UK children-an emerging problem[J]. Diabet Med, 2000,17(12) :867-871.
  • 3STEFANOVIC V, ANTIC S, MITIC-ZLATKOVIC M, et al.Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin[J]. Diabetes Metab Res Rev,1999, 15(6) :400-404.
  • 4李启富,李蓉,罗蓉,汪志红,刘智平,何军,粟绍初,李萍,张素华,舒昌达.西布曲明胶囊治疗单纯性肥胖[J].中国新药与临床杂志,2002,21(7):401-404. 被引量:6
  • 5李光伟,姜亚云,杨文英,郑辉,王金平,肖建中,胡泽溪,胡英华,潘孝仁.胰岛素抵抗及胰岛素分泌对2型糖尿病预防干预效果的影响──糖尿病预防干预策略探讨[J].中国糖尿病杂志,1999,7(3):131-134. 被引量:50
  • 6廖二元 超楚生.内分泌学[M].北京:人民卫生出版社,2001.610-611.

二级参考文献10

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2125
  • 2[1]KUCZMARSKI RJ, FLEGAL KM, CAMPBELL SM, et al. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991[J]. JAMA, 1994, 272(3):205-211.
  • 3[2]GOLDSTEIN DJ. Beneficial health effects of modest weight loss[J]. Int J Obesity, 1992, 16(6):397-415.
  • 4[3]BRAY GA, BLACKBURN GL, FERGUSON JM, et al. Sibutramine produces dose-related weight loss[J]. Obes Res, 1999, 7(2):189-198.
  • 5[4]MCNEELY W, GOA KL. Sibutramine: a review of its contribution to the management of obesity[J]. Drugs, 1998, 56(6):1093-1124.
  • 6[5]Van GAAL LF, WAUTERS MA, PEIFFER FW, et al. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?[J]. Int J Obesity, 1998, 22 Suppl 1: S38-S42.
  • 7李光伟,中华内科杂志,1998年,37卷,600页
  • 8Pan X R,Diabetes Care,1997年,20卷,537页
  • 9李光伟,中华内科杂志,1993年,32卷,656页
  • 10李光伟,胡英华,杨文英,姜亚云,曹辉碧,王金平,萧建中,胡泽溪,潘孝仁.胰岛素抵抗、胰岛素分泌功能对Ⅱ型糖尿病发生的影响[J].中华内科杂志,1998,37(9):600-604. 被引量:103

共引文献718

同被引文献6

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部